{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:21:12Z","timestamp":1777321272896,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.rceng.2022.02.008","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T16:00:30Z","timestamp":1654444830000},"page":"529-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recommendations for oral treatment for adult patients with type 1 Gaucher disease"],"prefix":"10.1016","volume":"222","author":[{"given":"M.\u00c1.","family":"Torralba-Cabeza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Morado-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pijierro-Amador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Fern\u00e1ndez-Canal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Villarrubia-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2022.02.008_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.rceng.2022.02.008_bib0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0020","author":"Scottish Intercollegiate Guidelines Network"},{"key":"10.1016\/j.rceng.2022.02.008_bib0025","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.rceng.2022.02.008_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet Med."},{"key":"10.1016\/j.rceng.2022.02.008_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev Endocrinol Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000440865","article-title":"Gaucher disease: clinical, biological and therapeutic aspects","volume":"83","author":"Dandana","year":"2016","journal-title":"Pathobiology."},{"key":"10.1016\/j.rceng.2022.02.008_bib0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"Mistry","year":"2011","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0060","first-page":"637","article-title":"A possible therapeutic approach to Krabbe\u00b4s globoid leukodystrophy and the status of cerebroside synthesis in the disorder","volume":"3","author":"Radin","year":"1972","journal-title":"Res Commun Chem Pathol Pharmacol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj J."},{"key":"10.1016\/j.rceng.2022.02.008_bib0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.35.8.1505566","article-title":"Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.rceng.2022.02.008_bib0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopatic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0080","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2165\/00003495-200363220-00006","article-title":"Miglustat","volume":"63","author":"McCormack","year":"2003","journal-title":"Drugs."},{"key":"10.1016\/j.rceng.2022.02.008_bib0085","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat tartrate for the treatment of adults with type I Gaucher disease","volume":"9","author":"Bennet","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.rceng.2022.02.008_bib0090","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","article-title":"Eliglustat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.rceng.2022.02.008_bib0095","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s40265-015-0468-9","article-title":"Eliglustat: a review in Gaucher disease type 1","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.rceng.2022.02.008_bib0100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0105","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2022.02.008_bib0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","article-title":"Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease","volume":"28","author":"Heitner","year":"2002","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007990802576518","article-title":"Goal-oriented therapy with miglustat in Gaucher disease","volume":"25","author":"Pastores","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.rceng.2022.02.008_bib0120","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.rceng.2022.02.008_bib0125","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.rceng.2022.02.008_bib0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J Inherit Metab Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.rceng.2022.02.008_bib0135","first-page":"S200","article-title":"A 2-year, prospective, open-label, non-inferiority study of miglustat as maintenance therapy in adults with type 1 Gaucher disease (GD1) stabilized on enzyme replacement therapy (ERT)","volume":"34","author":"Steiner","year":"2011","journal-title":"J. Inherit. Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.20504","article-title":"Guidance on the use of Miglustat for treating patients with type 1 Gaucher disease","volume":"80","author":"Weinreb","year":"2005","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0145","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.rceng.2022.02.008_bib0150","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.rceng.2022.02.008_bib0170","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0175","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.rceng.2022.02.008_bib0180","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.rceng.2022.02.008_bib0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","article-title":"Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial","volume":"123","author":"Charrow","year":"2018","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0190","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/ajh.25875","article-title":"Real-world effectiveness of eliglustat in treatment-na\u00efve and swich patients enrolled in the International Collaborative Gaucher Group Registry","volume":"95","author":"Mistry","year":"2020","journal-title":"Am J Haematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0195","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2022.02.008_bib0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rceng.2022.02.008_bib0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2019.11.002","article-title":"Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1","volume":"129","author":"Li","year":"2020","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2020.01.001","article-title":"Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents","volume":"129","author":"Thibault","year":"2020","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0220","first-page":"17","article-title":"Clinical response to eliglustat in treatment-na\u00efve patients with Gaucher disease type 1: post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry","volume":"8","author":"Ibrahim","year":"2016","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.rceng.2022.02.008_bib0225","first-page":"25","article-title":"Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: a sub-analysis of the eliglustat ENCORE trial","volume":"9","author":"Pleat","year":"2016","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.rceng.2022.02.008_bib0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/jrpp.jrpp_33_24","article-title":"The clinical efficacy of imiglucerase versus eliglustat in patients with Gaucher\u2019s disease type 1: a systematic review","volume":"7","author":"Nabizadeh","year":"2018","journal-title":"J Res Pharm Pract."},{"key":"10.1016\/j.rceng.2022.02.008_bib0235","first-page":"1002","article-title":"Budget impact analysis of eliglustat for the treatment of Gaucher disease type 1 in the United States","volume":"24","author":"Nalysnyk","year":"2018","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.rceng.2022.02.008_bib0240","unstructured":"Ficha t\u00e9cnica Miglustat: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavesca-epar-product-information_es.pdf (\u00faltimo acceso: noviembre 2021)."},{"key":"10.1016\/j.rceng.2022.02.008_bib0245","unstructured":"Ficha t\u00e9cnica Eliglustat: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerdelga-epar-product-information_es.pdf (\u00faltimo acceso: noviembre 2021)."},{"key":"10.1016\/j.rceng.2022.02.008_bib0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur J Int Med."},{"key":"10.1016\/j.rceng.2022.02.008_bib0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ymgme.2020.09.003","article-title":"How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations","volume":"131","author":"Ruskin","year":"2020","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.rceng.2022.02.008_bib0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jmd2.12172","article-title":"Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during Eliglustat clinical trials","volume":"57","author":"Lukina","year":"2020","journal-title":"JIMD Reports."},{"key":"10.1016\/j.rceng.2022.02.008_bib0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rceng.2022.02.008_bib0275","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12325-014-0174-0","article-title":"Management of bone disease in Gaucher disease type 1: clinical practice","volume":"31","author":"Giuffrida","year":"2014","journal-title":"Adv Ther."},{"key":"10.1016\/j.rceng.2022.02.008_bib0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rceng.2022.02.008_bib0285","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.12379","article-title":"A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease","volume":"93","author":"Di Rocco","year":"2008","journal-title":"Haematologica."},{"key":"10.1016\/j.rceng.2022.02.008_bib0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet Med."},{"key":"10.1016\/j.rceng.2022.02.008_bib0295","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rceng.2022.02.008_bib0300","series-title":"Medical Genetics Summaries [Internet]","article-title":"Eliglustat Therapy and CYP2D6 Genotype 2020 Dec 22","author":"Kane","year":"2012"},{"key":"10.1016\/j.rceng.2022.02.008_bib0305","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887422000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887422000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:49:58Z","timestamp":1762418998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887422000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2254887422000431"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2022.02.008","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for oral treatment for adult patients with type 1 Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2022.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2022.02.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}